Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Ren, Shengxiang; Zhou, Shunhua; Wu, Fengyin; Zhang, Ling; Li, Xuefei; Zhang, Jie; Xu, Jianfang; Lv, Meijun; Zhou, Caicun

doi:10.1016/j.lungcan.2011.05.023

Cited by 34 publications

(32 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No additional studies were identified from the references cited in the published studies that were searched for manually. Twenty-nine studies concerning the ERCC1 C118T/C8092A polymorphism , eight with the C8092A polymorphism (19,22,24,31,39,40,(48)(49), 12 with the XPD A751C polymorphism (26,27,39,47,(49)(50)(51)(52)(53)(54)(55)(56), three with XPA G23A (57)(58)(59) and five studies with XPG His46His (58)(59)(60)(61)(62). The specific process of the inclusion and exclusion of eligible studies is shown in Fig.…”

Section: Resultsmentioning

confidence: 99%

Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies

Huang

Zhou

2014

Biomedical Reports

View full text Add to dashboard Cite

RR, 1.22; 95% CI, 1.11-1.36; and P=0.00]. No significant association between the and polymorphisms and tumor response was found. There was also no evidence found to support the use of the and polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC in the meta-analysis. For the polymorphisms, a significant association with an objective response was detected. Multiple and large-scale studies are required to further investigate the association between biomarkers and tumor prognosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies

Huang

Zhou

2014

Biomedical Reports

View full text Add to dashboard Cite

show abstract

“…However the results have been inconclusive, which might explain why we only got two hits in our literature-based approach. DNA-repair genes have previously been shown to play a role in the pharmacogenetics of platinum-based effects (28,29,32). One of our hits in the literature-based approach was a genetic variant in ERCC5, a DNA-repair gene, but this variant the genotyping failed in the validation cohort and it has a low minor allele frequency.…”

Section: Discussionmentioning

confidence: 99%

Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities

Gréen

Hasmats

Kupershmidt

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Chemotherapies are associated with significant interindividual variability in therapeutic effect and adverse drug reactions. In lung cancer, the use of gemcitabine and carboplatin induces grade 3 or 4 myelosuppression in about a quarter of the patients, while an equal fraction of patients is basically unaffected in terms of myelosuppressive side effects. We therefore set out to identify genetic markers for gemcitabine/carboplatin-induced myelosuppression.Experimental Design: We exome sequenced 32 patients that suffered extremely high neutropenia and thrombocytopenia (grade 3 or 4 after first chemotherapy cycle) or were virtually unaffected (grade 0 or 1). The genetic differences/polymorphism between the groups were compared using six different bioinformatics strategies: (i) whole-exome nonsynonymous single-nucleotide variants association analysis, (ii) deviation from Hardy-Weinberg equilibrium, (iii) analysis of genes selected by a priori biologic knowledge, (iv) analysis of genes selected from gene expression meta-analysis of toxicity datasets, (v) Ingenuity Pathway Analysis, and (vi) FunCoup network enrichment analysis.Results: A total of 53 genetic variants that differed among these groups were validated in an additional 291 patients and were correlated to the patients' myelosuppression. In the validation, we identified rs1453542 in OR4D6 (P ¼ 0.0008; OR, 5.2; 95% CI, 1.8-18) as a marker for gemcitabine/carboplatin-induced neutropenia and rs5925720 in DDX53 (P ¼ 0.0015; OR, 0.36; 95% CI, 0.17-0.71) as a marker for thrombocytopenia. Patients homozygous for the minor allele of rs1453542 had a higher risk of neutropenia, and for rs5925720 the minor allele was associated with a lower risk for thrombocytopenia.Conclusions: We have identified two new genetic markers with the potential to predict myelosuppression induced by gemcitabine/carboplatin chemotherapy. Clin Cancer Res; 22(2); 366-73.Ó2015 AACR.

show abstract

“…Multiple previous studies have reported that ERCC1 and ERCC2 were associated with the response to cisplatin-based chemotherapy and clinical outcome in several cancers (Kamikozuru et al, 2008;Park et al, 2011;Cheng et al, 2012;Ren et al, 2012;Chen et al, 2013;Rumiato et al, 2013;Gao et al, 2014;Li et al, 2014b). Park et al (2011) reported that the ERCC1 rs3212986 polymorphism was correlated with treatment outcome of metastatic gastric cancer treated with cisplatin-based chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…Kamikozuru et al (2008) found that ERCC1 rs11615 was negative associated with risk of death in patients with pancreatic cancer treated with platinum-based chemotherapy. Ren et al (2012) indicated that AAT codons of ERCC1 rs11615 might be a predictive marker for patients with non-small cell lung carcinoma (NSCLC) treated with platinum-based chemotherapy. Cheng et al (2012) found that the C allele of ERCC1 rs11615 polymorphism was associated with longer response to cisplatin-based chemotherapy in treatment of last-stage NSCLC than T allele.…”

Section: Discussionmentioning

confidence: 99%

Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma

Jiang

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. We aimed to evaluate the influence of four SNPs in ERCC1 and ERCC2 on the response to cisplatin-based treatment and on clinical outcome in patients with osteosarcoma. We identified 186 patients with osteosarcoma diagnosed between April 2009 and April 2011 who were eligible for inclusion in our study. Genotyping of ERCC1 rs11615, rs3212986, and rs2298881; and ERCC2 rs1799793 and rs13181 was conducted by a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. By conditional logistic regression analysis, patients carrying the CC genotypes of ERCC1 rs11615 and rs2298881 were shown to be more likely to have good response to chemotherapy when compared with patients carrying wildtype genotypes; the ORs (95%CIs) were 2.56 (1.02-7.35) and 3.01 (1.07-9.71), respectively. By Cox regression analysis, individuals carrying the CC genotype of ERCC1 rs11615 were associated with longer overall survival time and decreased risk of death from osteosarcoma; the hazards 10146 Z.H. Cao et al. ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (3): 10145-10151 (2015) ratio (95%CI) was 0.32 (0.07-0.98). In summary, our results suggested that the ERCC1 rs11615 and rs2298881 polymorphisms play important roles in the response to chemotherapy mediated by the DNA repair pathway and in the clinical outcome of osteosarcoma.

show abstract

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Cited by 34 publications

References 38 publications

Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies

Nucleotide excision repair gene polymorphisms and prognosis of non-small cell lung cancer patients receiving platinum-based chemotherapy: A meta-analysis based on 44 studies

Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities

Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma

Contact Info

Product

Resources

About